Melanoma & Skin Cancer | Specialty

Pre-Chemo Abiraterone Extends Survival in CRPC

November 21st 2014

ADT With GnRH Antagonists in Prostate Cancer

November 21st 2014

Upcoming Advances for GU Cancers

November 21st 2014

Latest News & Insight: November 20, 2014

November 21st 2014

Nivolumab Extends Survival in Phase III Melanoma Study

November 17th 2014

Frontline treatment with nivolumab significantly extended OS and PFS compared with dacarbazine in patients with untreated BRAF wild-type advanced melanoma.

Pembrolizumab Improves PFS, ORR Versus Chemotherapy in Phase II Melanoma Study

November 16th 2014

The PD-1 inhibitor pembrolizumab significantly improved PFS by over 43% compared with chemotherapy as a treatment for patients with metastatic melanoma who were refractory to ipilimumab.

Adding GM-CSF to Ipilimumab Improves OS, Lowers Toxicity in Advanced Melanoma

November 5th 2014

The addition of the GM-CSF agent sargramostim to the CTLA-4 inhibitor ipilimumab (Yervoy) prolonged overall survival (OS) and lowered toxicity for patients with unresectable stage III or IV melanoma

New Study Links Socioeconomic Factors and Fashion Trends Over the Past Century to Increased Incidence of Melanoma

October 31st 2014

Researchers analyzed artwork, advertisements and leisure time activities to estimate historic changes in UV exposure

FDA Expands Approval of Lymphoseek to Breast Cancer and Melanoma

October 15th 2014

The FDA has expanded the approval of Lymphoseek (technetium Tc 99m tilmanocept) injection to include lymphatic mapping in solid tumors and sentinel lymph node (SLN) detection for breast cancer and melanoma

Crossing Therapeutic Boundaries: Molecular Profiling May Help Move Noncancer Drugs Into Oncology Settings

October 1st 2014

One of the most striking changes in our understanding of the fundamental biology of malignant disease has been the observation that "driver" molecular abnormalities may frequently cross major histologic barriers.

Dabrafenib/Trametinib Combo Improves Survival Over Vemurafenib in Phase III COMBI-v Trial

September 30th 2014

Patients with unresectable melanoma had a significant improvement in the odds of survival when treated in first line with a combination of BRAF and MEK inhibitors, as opposed to anti-BRAF monotherapy

Combination BRAF, MEK Inhibition "New Standard" for Previously Untreated BRAF-Mutant Melanoma

September 29th 2014

Inhibiting BRAF and MEK at the same time improves progression-free survival (PFS) more so than BRAF inhibition alone in patients with BRAF V600 mutation-positive metastatic melanoma, according to results of a phase III placebo-controlled trial.

Dr. Weber on Nivolumab Versus Chemotherapy in Advanced Melanoma

September 29th 2014

Jeffrey S. Weber, MD, PhD, discusses the results of a phase III study of nivolumab compared with investigator's choice chemotherapy for the treatment of patients with advanced melanoma after prior anti-CTLA-4 therapy.

Nivolumab Beats Chemotherapy as Second-Line Treatment for Advanced Melanoma

September 29th 2014

Treatment with nivolumab (Opdivo) demonstrated superior objective response rates (ORR) and longer durations of response compared with chemotherapy in a phase III trial of patients with previously treated advanced metastatic melanoma, reported Jeffrey Weber, MD, at the 2014 ESMO Congress.

Dr. Kluger on a Phase I Trial of Concurrent Nivolumab and Ipilimumab

September 28th 2014

Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, discusses the results from a phase I trial of nivolumab and ipilimumab for the treatment of patients with advanced melanoma.

FDA Grants Priority Review to Nivolumab in Melanoma

September 26th 2014

The FDA has assigned a priority review designation to the PD-1 inhibitor nivolumab (Opdivo) as a treatment for pretreated patients with advanced melanoma.

Fresh Approaches for Treating Micro-Metastatic Melanoma Explored

September 18th 2014

Approximately 85% of patients with newly diagnosed melanoma present with what appears to be clinically localized disease, making them candidates for standard treatment with surgery.

UCLA Researcher Provides Insight Into the Impact of Pembrolizumab in Melanoma

September 13th 2014

To gain further insight into the approval of pembrolizumab, OncLive interviewed John Glaspy, MD, MPH, from the Jonsson Comprehensive Cancer Center at UCLA, where research into the novel drug was conducted.

Combination BRAF-MEK Inhibition With Dabrafenib and Trametinib for BRAF-Mutant Melanoma

September 10th 2014

It is estimated that in 2014 more than 76,000 people will be diagnosed with melanoma and approximately 9700 people will die from the malignancy.

Dr. Andtbacka on T-VEC Plus Ipilimumab in Unresected Melanoma

September 8th 2014

Robert H. I. Andtbacka, MD, CM, from Intermountain Healthcare and Huntsman Cancer Institute, discusses the safety and efficacy of T-VEC in combination with ipilimumab in patients with previously untreated, unresected stage IIIB-IV melanoma.